

Molecular identification of *Pseudomonas aeruginosa* recovered from cystic fibrosis patients

M. DOURAGHI^{1,2}, F. GHASEMI¹, M.M. SOLTAN DALLAL^{1,2}, M RAHBAR^{3,4}, A. RAHIMIFOROUSHANI⁵

¹ Division of Bacteriology, Department of Pathobiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran; ² Food Microbiology Research Center, Tehran University of Medical Sciences, Tehran, Iran; ³ Department of Microbiology, Iranian Reference Health Laboratory Research Center Ministry of Health and Medical Education, Tehran, Iran; ⁴ Antimicrobial Resistance Research Center, Iran University of Medical sciences, Tehran, Iran; ⁵ Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

Key words

Pseudomonas aeruginosa • cystic fibrosis • *oprI* • *oprL*

Summary

Objective. Precise identification of various morphotypes of *Pseudomonas aeruginosa* which developed during cystic fibrosis (CF) is of prime importance. We aimed to identify the isolates of *P. aeruginosa* recovered from CF patients at the genus and species level through primers targeting *oprI* and *oprL* genes via PCR.

Methods. Sputum samples or throat swabs were taken from 100 CF patients and plated on cetrimide agar. All suspected colonies were primarily screened for *P. aeruginosa* by a combination of phenotypic tests. Molecular identification of colonies was performed using specific primers for *oprI* and *oprL* genes.

Results. Based on phenotypic tests, *P. aeruginosa* isolates were recovered from 40% of CF patients. Forty isolates yielded amplicon of *oprI* gene using genus-specific primers confirming the identity of fluorescent pseudomonads. However, 37 of 40 isolates yielded amplicon of *oprL* gene using species-specific primers, verifying the identity of *P. aeruginosa*.

Conclusion. This study showed that the species-specific PCR targeting *oprL* gene can be used as accurate test for identification of highly adaptable *P. aeruginosa* in CF patients. This procedure may provide a simple and reliable method for identification of various morphotypes.

Introduction

Pseudomonas aeruginosa is considered as the most common recovered bacterium from respiratory infections in cystic fibrosis (CF) patients [1]. Cystic fibrosis is a genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) encoding gene. CFTR primarily acts as a chloride ion channel and mutation in this gene affects the chloride transport and sodium absorption, leading to thickness of mucus in lungs [2]. CFTR is also recognized as a cellular receptor for binding and clearance of *P. aeruginosa* from the lungs [3], therefore malfunction of CFTR may lead to persistence of this species and ultimately severe pulmonary disease. CF patients are more prone to colonization by a variety of bacteria during their life [4] but the majority of CF patients endure *P. aeruginosa* chronic lung infections [5]. The early colonization of patients may occur by susceptible and non-mucoid strains of *P. aeruginosa*, but as early as the colonized bacteria are covered by thickened and dehydrated mucosa in lung, the bacterial microenvironment will be established. This microenvironment creates a way for evasion of bacteria and a barrier to antibiotics and consequently selection of variants of *P. aeruginosa* [6]. Despite the prolonged antibiotic therapy, *P. aeruginosa* is not eradicated in such patients and the formation of various morphotypes

of bacteria during chronic and sustained infection is reported worldwide. The major morphologic alterations of *P. aeruginosa* in CF patients are conversion to mucoid variants, loss of pigments, overproduction of alginate, formation of small-colony variants, and evolution of mutator strains [7-10].

The emergence of mucoid variants *P. aeruginosa* is usually considered as a poor prognostic indicator in CF patients [11]. One of the critical control measures in CF patients is accurate species identification. The broad phenotypic variation of *P. aeruginosa* may lead to misidentification of these strains in CF patients. Therefore, precise identification of various morphotypes which developed during chronic infections and differentiation of *P. aeruginosa* from other non-fermentative strains involving in the pathogenesis of CF is of prime importance. Due to drawbacks of phenotypic methods for identification of *P. aeruginosa* morphotypes, we aimed to identify *P. aeruginosa* at the genus and species level through primers targeting *oprI* and *oprL* genes via PCR.

Materials and methods

In this cross-sectional study, the cases that had a sweat chloride equal to or greater than 60 mmol/L and were diagnosed as CF patients were included. The patients who

treated with antibiotics within the previous two weeks were excluded. One hundred patients suffering from CF, aged 1 to 23 years were studied from three health centers in Tehran during 2011 to 2012. Demographic characteristics and medical histories were collected from medical records. The study was approved by the local ethical committees.

Sputum samples or throat swabs were taken and cultured on cetrimide agar, blood agar and MacConkey agar and the plates were incubated for 72 h at 37 °C. Regardless of morphology of colonies, all suspected colonies primarily were screened for *P. aeruginosa* by a combination of tests including growth on cetrimide agar, growth at 42 °C, and biochemical tests such as oxidase, citrate, OF glucose, and arginine dihydrolase.

Genomic DNA extraction was performed using the standard phenol-chloroform extraction method [12]. Specific primers targeting the genes *oprI* and *oprL* were used to amplify 249 base pair (bp) and 504 bp products [13], respectively (Tab. I). Amplification of *oprI* and *oprL* was carried out in a total reaction volume of 20 µl containing 2 µl 10x PCR buffer, 1.5 mM MgCl₂, 0.2 mM deoxynucleotide, 0.25 mM each primer (Bioneer, Seoul, South Korea), 0.5 U *Taq* polymerase, and 10 ng DNA. The Thermocycler (PqLab, Germany) was set with the following conditions: Initial denaturation for 5 min at 95 °C and 30 cycles consisted of denaturation for 30s at 95°C, annealing for 30s at 57 °C, extension for 1 min at 72 °C, and final extension for 10 min at 72 °C. Electrophoresis was performed in a 1.5% agarose gel along with GeneRuler 100 bp DNA Ladder (Fermentas, Lithuania) and was stained with 0.5 µg/ml ethidium bromide. *Pseudomonas aeruginosa* ATCC 27853 was used as a positive control in all experiments.

Statistical analysis

The descriptive analysis was performed to calculate the frequency and percentage of variable using SPSS version 11.5.

Results

Among 100 patients with CF, 54 were females and 46 were males. Forty two patients were younger than 7 years old, 38 aged 7 to 14 years, and 20 aged more than 14 years. Demographic characteristics of CF patients including age and gender is shown in Fig. 1.

Based on phenotypic tests, *P. aeruginosa* isolates were

Fig. 1. Distribution of patients with cystic fibrosis in relation of age and gender.





Fig. 2. Distribution of *P. aeruginosa* colonized patients suffering from cystic fibrosis in relation of age and gender.




recovered from 40% of CF patients. The distribution of CF patients colonized with *P. aeruginosa* in relation to demographic characteristics is shown in Fig. 2. *P. aeruginosa* were recovered from females (n = 19, 47.5%) and males (n = 21, 52.5%) in approximately similar frequency and no statistically significant difference was found. The colonization rate by *P. aeruginosa* among various age groups was different. An increasing trend of *P. aeruginosa* colonization was seen ranging from 23.8% in the 1-7 years age group to 36.8% in the 7-14 years age group, and 80% in cases older than 14 years.

For each isolate, the distinct morphotypes either mucoid or non-mucoid colonies grown on cetrimide agar were primarily identified as *P. aeruginosa* which oxidase- and citrate-positive but were OF glucose nonfermenter. Subsequently, all morphotypes were distinguished from oth-

Tab. I. Specific primers sequences targeting *oprI* and *oprL*.


Amplicon size (bp)	Primer sequence (5'-3')	Target region
249	5'- ATGAACAACGTTCTGAAATCTCT -3' 5'- CTGCGGCTGGCTTTTCCAG -3'	oprI
504	5'- ATGGAAATGCTGAAATTCGGC -3' 5'- CTCTTCAGCTCGACGCGACG -3'	oprL

Fig. 3. The *oprI* gene amplification using specific primers yielded a product of 249 bp typical to *Pseudomonas* genus. L: 100 bp ladder (Fermentas, Lithuania); P: Positive control; 1-3: *Pseudomonas* isolates of CF patients; N: Negative control (distilled water).



er members of fluorescent pseudomonads by growth at 42 °C. Among 40 isolates of *P. aeruginosa*, 19 (47.5%) and 17 (42.5%) were mucoid and non-mucoid, respectively. In remaining isolates (n = 4, 10%) both mucoid and non-mucoid colonies were observed. Four (10%) and 17 (42.5%) isolates were arginine dihydrolase negative and non-pigmented, respectively. According to the combination of phenotypic and biochemical tests, 40 CF isolates were identified as *P. aeruginosa* and were considered for further identification via PCR-based assays. Forty isolates yielded 249 bp (Fig. 3) amplicon through amplification of *oprI* gene using genus specific primers confirming the identity of fluorescent pseudomonads. However, 37 of 40 isolates yielded 573 bp (Fig. 4) am-

Fig. 4. The *oprI* gene amplification using specific primers yielded a product of 504bp typical to *P. aeruginosa*. L: 100 bp ladder (Fermentas, Lithuania); P: Positive control; 1-7: *P. aeruginosa* isolates of CF patients; N: Negative control (distilled water).



plicon through amplification of *oprL* gene using species specific primers, verifying the identity of *P. aeruginosa*. Three isolates were identified as *P. aeruginosa* by phenotypic tests but did not confirmed via species specific PCR.

Discussion

P. aeruginosa is not a fastidious organism and the identification of clinical isolates of *P. aeruginosa* is usually based on phenotypic methods. The phenotypic tests including macroscopic characteristics and biochemical tests are the most reliable tests for identification of typical isolates of *P. aeruginosa* [14]. However, extensive alterations in phenotype of *P. aeruginosa* may occur during chronic infection. For instance, the microenvironment of the CF lung may provide suitable conditions for mutation and selection of unique population of colonized bacteria [15]. Conversion to mucoid and non-pigmented colonies is common in *P. aeruginosa* recovered from CF patients. On the other hand, CF lungs may be colonized with other non-fermentative Gram-negative bacilli which are not easily differentiated from *P. aeruginosa*. These limitations may result in misidentification of *P. aeruginosa* as the most frequent pathogen in CF respiratory samples [16]. Inaccurate identification may affect the antibiotic susceptibility testing, administration of effective antipseudomonal antibiotics, and patient care. In the current study, we identified some of isolates with atypical phenotype; the isolates which non-pigmented and some isolates display a negative reaction for arginine dihydrolase. A possible explanation for these findings might be the plasticity and adaptation of *P. aeruginosa* in response to the unusual environment in CF lungs during chronic infection. As the isolates of *P. aeruginosa* with atypical phenotype were observed, we considered both mucoid and non-mucoid as well as pigmented and non-pigmented colonies for molecular identification. In this study, we determined the identity of multiple morphotypes of *P. aeruginosa* recovered from Iranian patients suffering from CF based on PCR assays. To minimize the potential error of single-target assays, we used two targets for molecular identification of *P. aeruginosa*. We used PCR targeting two genes; *oprI* and *oprL* which are peptidoglycan associated outer membrane lipoproteins. *oprI* gene was previously identified as a conserved gene in members of fluorescent pseudomonads and in *Pseudomonadaceae* family. As reported previously, *oprI* gene sequence is highly conserved in *P. aeruginosa* isolates [18]. We found that amplicon of *oprI* gene were detected in all the phenotypically identified isolates including mucoid and non-pigmented *Pseudomonas*. This finding indicates that all isolates are more likely a member of fluorescent pseudomonads or *Pseudomonas* genus. These results are consistent with previous studies that applied *oprI* gene for identification of *Pseudomonas* genus [13, 19]. Moreover, we identified the *P. aeruginosa* at the species level using *oprL* gene specific primers. Our findings indicate

that the majority of isolates were *P. aeruginosa* and three isolates belonged to *Pseudomonas* genus as amplified only through genus-specific primers and these isolates were misidentified via phenotypic methods. This study also demonstrated that non-aeruginosa species may isolated from CF patients. The discrepancy between the results of phenotypic assays and molecular tests was not statistically significant, but species-specific PCR is more reliable and sensitive method for identification of morphotypes of *P. aeruginosa*.

This study showed that the species specific PCR targeting *oprL* gene can be used as accurate test for identification of highly adaptable *P. aeruginosa* in CF patients. This procedure may provide a simple and reliable method for identification of various morphotypes which misidentified via phenotypic methods.

References

- [1] Rowe SM, Miller S, Sorscher EJ. *Cystic fibrosis*. N Engl J Med 2005;352:1992-2001.
- [2] Ratjen F, McColley SA. *Update in cystic fibrosis 2011*. Am J Respir Crit Care Med 2012;185:933-6.
- [3] Pier GB, Grout M, Zaidi TS. *Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung*. PNAS 1997;94:12088-93.
- [4] Hart CA, Winstanley C. *Persistent and aggressive bacteria in the lungs of cystic fibrosis children*. Br Med Bull 2002;61:81-96.
- [5] Starmer TD, McCray PB. *Pathogenesis of early lung disease in cystic fibrosis: a window of opportunity to eradicate bacteria*. Ann Intern Med 2005;143:816-22.
- [6] Hassett DJ, Sutton MD, Schurr MJ, Herr AB, et al. *Pseudomonas aeruginosa hypoxic or anaerobic biofilm infections within cystic fibrosis airways*. Trends Microbiol 2009;17:130-8.
- [7] Mathee K, Ciofu O, Sternberg C, et al. *Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung*. Microbiology 1999;145:1349-57.
- [8] Worlitzsch D, Tarran R, Ulrich M, et al. *Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients*. J Clin Invest 2002;109:317-25.
- [9] Oliver A, Cantón R, Campo P, et al. *High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection*. Science 2000;288:1251-53.
- [10] Ciofu O, Mandsberg LF, Bjarnsholt T, et al. *Genetic adaptation of Pseudomonas aeruginosa during chronic lung infection of patients with cystic fibrosis: strong and weak mutators with heterogeneous genetic backgrounds emerge in mucA and/or lasR mutants*. Microbiology 2010;156:1108-119.
- [11] Emerson J, Rosenfeld M, McNamara S, et al. *Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis*. Pediatr Pulmonol 2002;34:91-100.
- [12] Sambrook J, Fritsch EF, Maniatis T. *Molecular cloning*, 2nd ed. New York: Cold Spring Harbor Laboratory Press 1989.
- [13] De Vos D, Lim A, Pirnay JP, et al. *Direct detection and identification of Pseudomonas aeruginosa in clinical samples such as skin biopsy specimens and expectorations by multiplex PCR based on two outer membrane lipoprotein genes, oprI and oprL*. J Clin Microbiol 1997;35:1295-9.
- [14] Miller MB, Gilligan PH. *Laboratory aspects of management of chronic pulmonary infections in patients with cystic fibrosis*. J Clin Microbiol 2003;41:4009-15.
- [15] Burns JL, Emerson J, Stapp JR, et al. *Microbiology of sputum from patients at cystic fibrosis centers in the United States*. Clin Infect Dis 1998;27:158-63.
- [16] Kidd TJ, Ramsay KA, Hu H, et al. *Low rates of Pseudomonas aeruginosa misidentification in isolates from cystic fibrosis patients*. J Clin Microbiol 2009;47:1503-9.
- [17] Wessel AK, Liew J, Kwon T, et al. *Role of Pseudomonas aeruginosa peptidoglycan-associated outer membrane proteins in vesicle formation*. J Bacteriol 2013;195:213-9.
- [18] De Vos D, Bouton C, Samiguet A, et al. *Sequence diversity of the oprI gene, coding for major outer membrane lipoprotein I, among rRNA group I pseudomonads*. J Bacteriol 1998;180:6551-6.
- [19] De Vos D, Lim Jr.A, De Vos P, et al. *Detection of the outer membrane lipoprotein I and its gene in fluorescent and non fluorescent pseudomonads: implications for taxonomy and diagnosis*. J Gen Microbiol 1992;139:2215-23.

■ Received on January 19, 2014. Accepted on May 26, 2014.

■ Correspondence: Mohammad Mehdi Soltan Dallal, Food Microbiology Research Center and School of Public Health, Tehran University of Medical Sciences, Tehran, Iran - Tel. +98 21 8899297 - Fax +98 21 88954913 - E-mail: msoltandallal@gmail.com